All In Biotech

Drug Trial Radar · NCT07661329

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

A Comparative Randomized, Investigator-Blind, Active-Controlled, Parallel-Group, Multicenter, Clinical Endpoint Study to Evaluate Efficacy and Safety of Bimatoprost Ophthalmic Solution 0.01% (YSBP) of YS Life Science Co., Ltd. (YSLS) and Lumigan® (Bimatoprost Ophthalmic Solution) 0.01% of AbbVie INC, in the Treatment of Subjects With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH).

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 2, 2026

Primary completion

Nov 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
YS Life Science Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.

Conditions

  • Primary Open Angle Glaucoma (POAG)
  • Ocular Hypertension (OH)

Interventions

  • Bimatoprost ophthalmic solution 0.01% YSBPDrug

    YSBP

  • bimatoprost ophthalmic solution 0.01% (Lumigan®)Drug

    Lumigan®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intra-Ocular PressureTime frame: Week 12

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • National Clinical Trials

    Beverly Hills, California · Not yet recruiting

  • United medical research institute

    Inglewood, California · Not yet recruiting

  • Eye research foundation, Inc.

    Newport Beach, California · Recruiting

  • Visionary Eye Research Institute

    Newport Beach, California · Not yet recruiting

  • North Bay Eye Associates

    Petaluma, California · Not yet recruiting

  • Advanced research, LLC

    Boynton Beach, Florida · Not yet recruiting

  • Advanced research, LLC

    Weston, Florida · Not yet recruiting

  • Clayton Eye Clinical Research

    Morrow, Georgia · Not yet recruiting

  • Coastal Research Associates, LLC

    Roswell, Georgia · Not yet recruiting

  • The eye care institute

    Louisville, Kentucky · Not yet recruiting

  • Tekwani vision center

    St Louis, Missouri · Not yet recruiting

  • Ophthalmology associate (Eye care)

    St Louis, Missouri · Not yet recruiting

  • Houston Eye Associates

    Houston, Texas · Not yet recruiting

  • R and R eye research

    San Antonio, Texas · Not yet recruiting

  • Jyoti eye hospital

    Ahmedabad, Gujarat, India · Not yet recruiting

  • M&J western regional institute of ophthalmology

    Ahmedabad, Gujarat, India · Not yet recruiting

  • GMERS medical college and civil hospital sola

    Ahmedabad, Gujarat, India · Not yet recruiting

  • Netralaya super speciality eye care hospital

    Ahmedabad, Gurajat, India · Not yet recruiting

  • Ambade eye hospital

    Nagpur, Maharashtra, India · Not yet recruiting

  • Dr. D. Y. Patil medical college hospital & research centre

    Nerul, Mumbai, India · Not yet recruiting

  • LV Prasad eye institute

    Bhubaneswar, Odisha, India · Not yet recruiting

  • Regional institute of ophthalmology

    Kolkata, West Bengal, India · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.